NASDAQ:TERN - Terns Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.50
  • Forecasted Upside: 145.60 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$10.79
▼ -0.38 (-3.40%)

This chart shows the closing price for TERN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Terns Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TERN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TERN

Analyst Price Target is $26.50
▲ +145.60% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Terns Pharmaceuticals in the last 3 months. The average price target is $26.50, with a high forecast of $32.00 and a low forecast of $21.00. The average price target represents a 145.60% upside from the last price of $10.79.

This chart shows the closing price for TERN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Terns Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021The Goldman Sachs GroupInitiated CoverageBuy$21.00High
3/2/2021JPMorgan Chase & Co.Initiated CoverageOverweight$32.00High
3/2/2021CowenInitiated CoverageOutperformHigh
3/2/2021The Goldman Sachs GroupInitiated CoverageBuy$29.00Medium
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

Terns Pharmaceuticals logo
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $10.79
Low: $10.79
High: $10.90

50 Day Range

MA: $10.47
Low: $7.22
High: $13.46

52 Week Range

Now: $10.79
Low: $6.91
High: $28.36

Volume

64 shs

Average Volume

111,780 shs

Market Capitalization

$271.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Terns Pharmaceuticals?

The following Wall Street analysts have issued reports on Terns Pharmaceuticals in the last twelve months: Cowen Inc, JPMorgan Chase & Co., The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for TERN.

What is the current price target for Terns Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Terns Pharmaceuticals in the last year. Their average twelve-month price target is $26.50, suggesting a possible upside of 137.2%. JPMorgan Chase & Co. has the highest price target set, predicting TERN will reach $32.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $21.00 for Terns Pharmaceuticals in the next year.
View the latest price targets for TERN.

What is the current consensus analyst rating for Terns Pharmaceuticals?

Terns Pharmaceuticals currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TERN will outperform the market and that investors should add to their positions of Terns Pharmaceuticals.
View the latest ratings for TERN.

How do I contact Terns Pharmaceuticals' investor relations team?

Terns Pharmaceuticals' physical mailing address is 1065 EAST HILLSDALE BLVD. SUITE 100, FOSTER CITY CA, 94404. The official website for Terns Pharmaceuticals is www.ternspharma.com.